These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 474044

  • 1. [Treatment of patients with hemophilia A having antibodies to factor VIII].
    Lopaciuk S, Ziemski JM.
    Acta Haematol Pol; 1979; 10(2):115-22. PubMed ID: 474044
    [Abstract] [Full Text] [Related]

  • 2. Effect of treatment with activated prothrombin complex concentrate (FEIBA) on factor VIII-antibody level.
    Lechner K, Nowotny C, Krinninger B, Zegner M, Deutsch E.
    Thromb Haemost; 1979 Feb 15; 40(3):478-85. PubMed ID: 425062
    [Abstract] [Full Text] [Related]

  • 3. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial.
    Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, van Geijlswijk JL, van Houwelingen H, van Asten P, Sixma JJ.
    N Engl J Med; 1981 Sep 24; 305(13):717-21. PubMed ID: 6790990
    [Abstract] [Full Text] [Related]

  • 4. [Importance of PPSB fraction in the treatment of hemophilia A with antibodies against factor VIII].
    Hrubisková K.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1980 Sep 24; 107(4):672-82. PubMed ID: 6162735
    [Abstract] [Full Text] [Related]

  • 5. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies.
    Buchanan GR, Kevy SV.
    Pediatrics; 1978 Nov 24; 62(5):767-74. PubMed ID: 724319
    [Abstract] [Full Text] [Related]

  • 6. The suppression of factor VIII antibodies in haemophilia.
    Dormandy KM, Sultan Y.
    Pathol Biol (Paris); 1975 Dec 24; 23 suppl():17-23. PubMed ID: 772555
    [Abstract] [Full Text] [Related]

  • 7. [Acquired hemophilia caused by autoantibodies against factor VIII coagulation activity. Clinical, biological study and therapeutic indications. Experience based on a study of 9 cases].
    Liozon E, Delaire L, Turlure P, Jaccard A, Loustaud-Ratti V, Réméniéras L, Julia A, Gaillard S, Bordessoule D, Vidal E.
    Ann Med Interne (Paris); 1997 Dec 24; 148(7):477-90. PubMed ID: 9538386
    [Abstract] [Full Text] [Related]

  • 8. Rapid decrease in high titer of factor VIII inhibitors upon immunosuppressive treatment in severe postpartum acquired hemophilia A.
    Pejsa V, Grgurević I, Kusec R, Gaćina P.
    Croat Med J; 2004 Apr 24; 45(2):213-6. PubMed ID: 15103761
    [Abstract] [Full Text] [Related]

  • 9. [Articular and muscular hemorrhages in hemophilia A with anti-factor VIII antibodies. Treatment with selected batches of PPSB (factor IX concentrate)].
    Verroust F, Moussard C, Allain JP.
    Presse Med; 1985 May 11; 14(19):1073-6. PubMed ID: 3158962
    [Abstract] [Full Text] [Related]

  • 10. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
    Engelfriet CP, Reesink HW, Mannucci PM, Gringeri A, Ingerslev J, Brettler DB, Mauser-Bunschoten EP, Negrier C, Berntorp E, Smith OP, Shapiro AD.
    Vox Sang; 2000 May 11; 78(4):256-61. PubMed ID: 10970234
    [No Abstract] [Full Text] [Related]

  • 11. Treatment of anti-factor VIII antibodies.
    Blatt PM, White GC, McMillan CW, Roberts HR.
    Thromb Haemost; 1977 Aug 31; 38(2):514-23. PubMed ID: 579493
    [Abstract] [Full Text] [Related]

  • 12. [Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].
    Meili EO, Dazzi H, von Felten A.
    Schweiz Med Wochenschr; 1995 Mar 04; 125(9):405-11. PubMed ID: 7892567
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial.
    Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM.
    N Engl J Med; 1980 Aug 21; 303(8):421-5. PubMed ID: 6771653
    [Abstract] [Full Text] [Related]

  • 14. Effects of low-dose 'factor VIII inhibitor bypassing activity (FEIBA)' in resistant haemophilia.
    Zwahlen H, Beck EA.
    Acta Haematol; 1980 Aug 21; 64(1):12-7. PubMed ID: 6774572
    [Abstract] [Full Text] [Related]

  • 15. Activated ppsb in the treatment of a patient with haemophilia and antibodies to factor VIII.
    Ekert H, McVeagh P.
    Med J Aust; 1975 Oct 25; 2(17):675-7. PubMed ID: 1207551
    [Abstract] [Full Text] [Related]

  • 16. [Paradoxical bleeding as a complication of the treatment of hemophilia with factor VIII and factor IX preparations].
    Sutor AH.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990 Oct 25; 117(4):595-9. PubMed ID: 1714865
    [Abstract] [Full Text] [Related]

  • 17. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
    Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P.
    Thromb Haemost; 1997 Jun 25; 77(6):1113-9. PubMed ID: 9241742
    [Abstract] [Full Text] [Related]

  • 18. Elective cardiac operation in a patient with severe hemophilia and acquired factor VIII antibodies.
    Leggett PL, Doyle D, Smith WB, Culpepper W, Cooper S, Ochsner JL.
    J Thorac Cardiovasc Surg; 1984 Apr 25; 87(4):556-60. PubMed ID: 6423912
    [Abstract] [Full Text] [Related]

  • 19. The use of non-activated prothrombin concentrate in the management of haemophilia A with factor VIII antibodies.
    Price DA, d'Souza S, Ekert H.
    Aust N Z J Med; 1977 Jun 25; 7(3):286-90. PubMed ID: 269689
    [Abstract] [Full Text] [Related]

  • 20. Activated factor IX complex in treatment of surgical cases of hemophilia A with inhibitors.
    Hanna WT, Madigan RR, Miles MA, Lange RD.
    Thromb Haemost; 1981 Oct 25; 46(3):638-41. PubMed ID: 6976016
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.